Search

Your search keyword '"Kitson, Sarah J."' showing total 30 results
Start Over Author "Kitson, Sarah J."
30 results on '"Kitson, Sarah J."'

1. Endometrial cancer

Author

Crosbie, Emma J, Kitson, Sarah J, McAlpine, Jessica N, Mukhopadhyay, Asima, Powell, Melanie E, and Singh, Naveena

Published
2022
Full Text
View/download PDF

3. Predicting risk of endometrial cancer in asymptomatic women (PRECISION): Model development and external validation.

Author

Kitson, Sarah J., Crosbie, Emma J., Evans, D. Gareth, Lophatananon, Aritaya, Muir, Kenneth R., Ashcroft, Darren, Kontopantelis, Evan, and Martin, Glen P.

Subjects
*ENDOMETRIAL cancer, *ASYMPTOMATIC patients, *DISEASE risk factors, *CANCER patients, *AKAIKE information criterion
Abstract

Objectives: Develop an endometrial cancer risk prediction model and externally validate it for UK primary care use. Design: Cohort study. Setting: The UK Biobank was used for model development and a linked primary (Clinical Practice Research Datalink, CPRD) and secondary care (HES), mortality (ONS) and cancer register (NRCAS) dataset was used for external validation. Population: Women aged 45–60 years with no history of endometrial cancer or hysterectomy. Methods: Model development was performed using a flexible parametric survival model and stepwise backward selection aiming to minimise the Akaike information criterion. Model performance on external validation was assessed through flexible calibration plots, calculation of the expected to observed ratio and C‐statistic and decision curve analysis. Main outcome measures: Endometrial cancer diagnosis within 1–10 years of the index date. Results: Model development included 222 031 women (902 incident endometrial cancer cases) and external validation 3 094 371 women (8585 endometrial cancer cases). The final model (with equation provided) incorporated age, body mass index, waist circumference, age at menarche, menopause and last birth, hormone replacement, tamoxifen and oral contraceptive pill use, type 2 diabetes, smoking and family history of bowel cancer. It was well calibrated on external validation (calibration slope 1.14, 95% confidence interval [CI] 1.11–1.17, E/O 1.03, 95% CI 1.01–1.05), with moderate/good discrimination (C‐statistic 0.70, 95% CI 0.69–0.70) and had improved net benefit compared with previously developed models. Conclusions: The Predicting risk of endometrial cancer in asymptomatic women model (PRECISION), using easily measurable anthropometric, reproductive, personal and family history, accurately quantifies a woman's 10‐year risk of endometrial cancer. Its use could determine eligibility for primary endometrial cancer prevention trials and for targeted resource allocation in UK general practices. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Supplementary table 1 from PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial

Author

Kitson, Sarah J., primary, Maskell, Zoe, primary, Sivalingam, Vanitha N., primary, Allen, Jennifer L., primary, Ali, Saad, primary, Burns, Sean, primary, Gilmour, Kyle, primary, Latheef, Rahamatulla, primary, Slade, Richard J., primary, Pemberton, Philip W., primary, Shaw, Joseph, primary, Ryder, W. David, primary, Kitchener, Henry C., primary, and Crosbie, Emma J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial

Author

Kitson, Sarah J., primary, Maskell, Zoe, primary, Sivalingam, Vanitha N., primary, Allen, Jennifer L., primary, Ali, Saad, primary, Burns, Sean, primary, Gilmour, Kyle, primary, Latheef, Rahamatulla, primary, Slade, Richard J., primary, Pemberton, Philip W., primary, Shaw, Joseph, primary, Ryder, W. David, primary, Kitchener, Henry C., primary, and Crosbie, Emma J., primary

Published
2023
Full Text
View/download PDF

14. Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study

Author

Paraskevaidi, Maria, Medeiros-De-morais, Camilo De lelis, Ashton, Katherine M., Stringfellow, Helen F., McVey, Rhona J., Ryan, Neil A.J., O’Flynn, Helena, Sivalingam, Vanitha N., Kitson, Sarah J., MacKintosh, Michelle L., Derbyshire, Abigail E., Pow, Cecilia, Raglan, Olivia, Lima, Kássio M.G., Kyrgiou, Maria, Martin-Hirsch, Pierre L., Martin, Francis, Crosbie, Emma J., Paraskevaidi, Maria, Medeiros-De-morais, Camilo De lelis, Ashton, Katherine M., Stringfellow, Helen F., McVey, Rhona J., Ryan, Neil A.J., O’Flynn, Helena, Sivalingam, Vanitha N., Kitson, Sarah J., MacKintosh, Michelle L., Derbyshire, Abigail E., Pow, Cecilia, Raglan, Olivia, Lima, Kássio M.G., Kyrgiou, Maria, Martin-Hirsch, Pierre L., Martin, Francis, and Crosbie, Emma J.

Abstract

Endometrial cancer is the sixth most common cancer in women, with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive or of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive approaches to facilitate the early detection and timely management of endometrial cancer. We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer (n = 342), its precursor lesion atypical hyperplasia (n = 68) and healthy controls (n = 242, total n = 652) using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and machine learning algorithms. We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for Type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively. Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test has the potential not only to differentially diagnose endometrial cancer but also to detect its precursor lesion atypical hyperplasia—the early recognition of which may allow fertility sparing management and cancer prevention.

Published
2020

16. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study

Author

Ryan, Neil A. J., primary, McMahon, Raymond, additional, Tobi, Simon, additional, Snowsill, Tristan, additional, Esquibel, Shona, additional, Wallace, Andrew J., additional, Bunstone, Sancha, additional, Bowers, Naomi, additional, Mosneag, Ioana E., additional, Kitson, Sarah J., additional, O’Flynn, Helena, additional, Ramchander, Neal C., additional, Sivalingam, Vanitha N., additional, Frayling, Ian M., additional, Bolton, James, additional, McVey, Rhona J., additional, Evans, D. Gareth, additional, and Crosbie, Emma J., additional

Published
2020
Full Text
View/download PDF

18. Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study

Author

Paraskevaidi, Maria, primary, Morais, Camilo L. M., additional, Ashton, Katherine M., additional, Stringfellow, Helen F., additional, McVey, Rhona J., additional, Ryan, Neil A. J., additional, O’Flynn, Helena, additional, Sivalingam, Vanitha N., additional, Kitson, Sarah J., additional, MacKintosh, Michelle L., additional, Derbyshire, Abigail E., additional, Pow, Cecilia, additional, Raglan, Olivia, additional, Lima, Kássio M. G., additional, Kyrgiou, Maria, additional, Martin-Hirsch, Pierre L., additional, Martin, Francis L., additional, and Crosbie, Emma J., additional

Published
2020
Full Text
View/download PDF

19. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome

Author

Crosbie, Emma J, Ryan, Neil AJ, Arends, Mark J, Bosse, Tjalling, Burn, John, Cornes, Joanna M, Crawford, Robin, Eccles, Diana, Frayling, Ian M, Ghaem-Maghami, Sadaf, Hampel, Heather, Kauff, Noah D, Kitchener, Henry C, Kitson, Sarah J, Manchanda, Ranjit, McMahon, Raymond FT, Monahan, Kevin J, Menon, Usha, Møller, Pål, Möslein, Gabriela, Rosenthal, Adam, Sasieni, Peter, Seif, Mourad W, Singh, Naveena, Skarrott, Pauline, Snowsill, Tristan M, Steele, Robert, Tischkowitz, Marc, Manchester International Consensus Group, Evans, D Gareth, Crosbie, Emma J [0000-0003-0284-8630], Evans, D Gareth [0000-0002-8482-5784], and Apollo - University of Cambridge Repository

Subjects
Ovarian Neoplasms, congenital, hereditary, and neonatal diseases and abnormalities, Consensus, Genital Neoplasms, Female, screening, nutritional and metabolic diseases, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms, Europe, Lynch syndrome, endometrial cancer, North America, surveillance, Humans, Mass Screening, Female, guidance, Early Detection of Cancer
Abstract

PURPOSE: There are no internationally agreed upon clinical guidelines as to which women with gynecological cancer would benefit from Lynch syndrome screening or how best to manage the risk of gynecological cancer in women with Lynch syndrome. The Manchester International Consensus Group was convened in April 2017 to address this unmet need. The aim of the Group was to develop clear and comprehensive clinical guidance regarding the management of the gynecological sequelae of Lynch syndrome based on existing evidence and expert opinion from medical professionals and patients. METHODS: Stakeholders from Europe and North America worked together over a two-day workshop to achieve consensus on best practice. RESULTS: Guidance was developed in four key areas: (1) whether women with gynecological cancer should be screened for Lynch syndrome and (2) how this should be done, (3) whether there was a role for gynecological surveillance in women at risk of Lynch syndrome, and (4) what preventive measures should be recommended for women with Lynch syndrome to reduce their risk of gynecological cancer. CONCLUSION: This document provides comprehensive clinical guidance that can be referenced by both patients and clinicians so that women with Lynch syndrome can expect and receive appropriate standards of care.

Published
2019

20. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome

Author

Crosbie, Emma J., primary, Ryan, Neil A.J., additional, Arends, Mark J., additional, Bosse, Tjalling, additional, Burn, John, additional, Cornes, Joanna M., additional, Crawford, Robin, additional, Eccles, Diana, additional, Frayling, Ian M., additional, Ghaem-Maghami, Sadaf, additional, Hampel, Heather, additional, Kauff, Noah D., additional, Kitchener, Henry C., additional, Kitson, Sarah J., additional, Manchanda, Ranjit, additional, McMahon, Raymond F.T., additional, Monahan, Kevin J., additional, Menon, Usha, additional, Møller, Pål, additional, Möslein, Gabriela, additional, Rosenthal, Adam, additional, Sasieni, Peter, additional, Seif, Mourad W., additional, Singh, Naveena, additional, Skarrott, Pauline, additional, Snowsill, Tristan M., additional, Steele, Robert, additional, Tischkowitz, Marc, additional, Sanchez, Angel Alonso, additional, Bolton, James, additional, Crosbie, Emma J., additional, Church, David, additional, Donnelly, Karen, additional, Edmondson, Richard J., additional, Evans, D. Gareth, additional, Gollop, Paula, additional, Goodman, Selina, additional, Hodgson, Shirley, additional, Lalloo, Fiona, additional, Lowry, Anne, additional, McVey, Rhona J., additional, Miles, Tracie, additional, Moeslein, Gabriela, additional, Moller, Pal, additional, Stormoken, Astrid, additional, Stringfellow, Helen, additional, Wallace, Andrew, additional, Whyte, Luciya, additional, Wilkinson, Nafisa, additional, Wilson, Godfrey, additional, Wilson, Jo, additional, and Wood, Nick, additional

Published
2019
Full Text
View/download PDF

24. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial

Author

Kitson, Sarah J., primary, Maskell, Zoe, additional, Sivalingam, Vanitha N., additional, Allen, Jennifer L., additional, Ali, Saad, additional, Burns, Sean, additional, Gilmour, Kyle, additional, Latheef, Rahamatulla, additional, Slade, Richard J., additional, Pemberton, Philip W., additional, Shaw, Joseph, additional, Ryder, W. David, additional, Kitchener, Henry C., additional, and Crosbie, Emma J., additional

Published
2019
Full Text
View/download PDF

26. Pre-Surgical Metformin in Uterine Malignancy (Premium): A Multi-Centre, Randomised Double-Blind, Placebo-Controlled Phase 3 Trial

Author

Kitson, Sarah J., primary, Maskell, Zoe, additional, Sivalingam, Vanitha N, additional, Allen, Jennifer L, additional, Ali, Saad, additional, Burns, Sean, additional, Gilmour, Kyle, additional, Latheef, Rahamatulla, additional, Slade, Richard J, additional, Pemberton, Phil, additional, Shaw, Joseph, additional, Ryder, W. David, additional, Kitchener, Henry C, additional, and Crosbie, Emma, additional

Published
2018
Full Text
View/download PDF

27. Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer

Author

Latif, Ayşe, primary, Chadwick, Amy L., additional, Kitson, Sarah J., additional, Gregson, Hannah J., additional, Sivalingam, Vanitha N., additional, Bolton, James, additional, McVey, Rhona J., additional, Roberts, Stephen A., additional, Marshall, Kay M., additional, Williams, Kaye J., additional, Stratford, Ian J., additional, and Crosbie, Emma J., additional

Published
2017
Full Text
View/download PDF

29. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome

Author

Crosbie, Emma J, Ryan, Neil AJ, Arends, Mark J, Bosse, Tjalling, Burn, John, Cornes, Joanna M, Crawford, Robin, Eccles, Diana, Frayling, Ian M, Ghaem-Maghami, Sadaf, Hampel, Heather, Kauff, Noah D, Kitchener, Henry C, Kitson, Sarah J, Manchanda, Ranjit, McMahon, Raymond FT, Monahan, Kevin J, Menon, Usha, Møller, Pål, Möslein, Gabriela, Rosenthal, Adam, Sasieni, Peter, Seif, Mourad W, Singh, Naveena, Skarrott, Pauline, Snowsill, Tristan M, Steele, Robert, Tischkowitz, Marc, Manchester International Consensus Group, and Evans, D Gareth

Subjects
Ovarian Neoplasms, congenital, hereditary, and neonatal diseases and abnormalities, Consensus, Genital Neoplasms, Female, screening, nutritional and metabolic diseases, Colorectal Neoplasms, Hereditary Nonpolyposis, 3. Good health, Endometrial Neoplasms, Europe, Lynch syndrome, endometrial cancer, North America, surveillance, Humans, Mass Screening, Female, guidance, Early Detection of Cancer
Abstract

PURPOSE: There are no internationally agreed upon clinical guidelines as to which women with gynecological cancer would benefit from Lynch syndrome screening or how best to manage the risk of gynecological cancer in women with Lynch syndrome. The Manchester International Consensus Group was convened in April 2017 to address this unmet need. The aim of the Group was to develop clear and comprehensive clinical guidance regarding the management of the gynecological sequelae of Lynch syndrome based on existing evidence and expert opinion from medical professionals and patients. METHODS: Stakeholders from Europe and North America worked together over a two-day workshop to achieve consensus on best practice. RESULTS: Guidance was developed in four key areas: (1) whether women with gynecological cancer should be screened for Lynch syndrome and (2) how this should be done, (3) whether there was a role for gynecological surveillance in women at risk of Lynch syndrome, and (4) what preventive measures should be recommended for women with Lynch syndrome to reduce their risk of gynecological cancer. CONCLUSION: This document provides comprehensive clinical guidance that can be referenced by both patients and clinicians so that women with Lynch syndrome can expect and receive appropriate standards of care.

30. Lay and general practitioner attitudes towards endometrial cancer prevention: a cross-sectional study.

Author

Kitson SJ, Khan U, and Crosbie EJ

Abstract

Background: Effective and targeted endometrial cancer prevention strategies could reduce diagnoses by 60%. Whether this approach is acceptable to individuals and general practitioners (GPs) is currently unknown. This study sought to determine attitudes towards the provision of personalised endometrial cancer risk assessments and the acceptability of potential prevention strategies., Methods: Specific online questionnaires were developed for individuals aged 45-60 years with a uterus and UK-practising GPs, with social media, charity websites, and email used to advertise the study. Individuals completed the questionnaires between February and April 2022., Results: Of 660 lay questionnaire respondents, 90.3% (n = 596) thought that undergoing an endometrial cancer risk assessment was a good or very good idea and 95.6% (n = 631) would be willing to undergo such an assessment. The commonest reasons for wanting to participate were "to try and reduce my risk" (n = 442, 67.0%), "to be informed" (n = 354, 53.6%), and "it could save my life' (n = 315, 47.7%). Over 80% of respondents would make lifestyle changes to reduce their endometrial cancer risk (n = 550), with half accepting a pill, Mirena, or hysterectomy for primary prevention. GPs were similarly engaged, with 93.0% (n = 106) willing to offer an endometrial cancer risk assessment if a tool were available, potentially during a Well Woman screen., Conclusion: Personalised endometrial cancer risk assessments are acceptable to potentially eligible individuals and GPs and could be accommodated within routine practice. Clinical trials to determine the effectiveness of lifestyle modification and Mirena for endometrial protection are urgently required and should be targeted at those at greatest disease risk., (© The Author(s) 2023. Published by Oxford University Press.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results